Neuberger Berman Group
RXRX icon

Neuberger Berman Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Neuberger Berman Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.8K Sell
24,478
-2,216
-8% -$7.38K ﹤0.01% 2256
2026
Q1 		$82K Buy
26,694
+2,684
+11% +$10.4K ﹤0.01% 2092
2025
Q4 		$98.2K Buy
24,010
+6,937
+41% +$34.4K ﹤0.01% 2018
2025
Q3 		$83.3K Sell
17,073
-80
-0.5% -$420 ﹤0.01% 1981
2025
Q2 		$86.8K Buy
17,153
+6,384
+59% +$31.4K ﹤0.01% 1970
2025
Q1 		$57K Buy
10,769
+469
+5% +$3.42K ﹤0.01% 1906
2024
Q4 		$69.6K Sell
10,300
-219,538
-96% -$1.48M ﹤0.01% 1869
2024
Q3 		$1.51M Sell
229,838
-125,801
-35% -$902K ﹤0.01% 1190
2024
Q2 		$2.67M Buy
+355,639
New +$3.1M ﹤0.01% 1046

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Neuberger Berman Group's RXRX Position: Q2 2026 in Review

Neuberger Berman Group reduced its Recursion Pharmaceuticals (RXRX) stake by 8.3% in Q2 2026, selling an estimated $7.38K and leaving 24,478 shares worth $89.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2256.

Neuberger Berman Group first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.67M in Q2 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Neuberger Berman Group held 24,478 shares of Recursion Pharmaceuticals worth $89.8K as of Q2 2026.
  • Neuberger Berman Group sold 2,216 Recursion Pharmaceuticals shares in Q2 2026, an estimated $7.38K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2256 holding.
  • Neuberger Berman Group first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Neuberger Berman Group's Recursion Pharmaceuticals position peaked at $2.67M in Q2 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.